Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 14.90B +104.3% |
| Revenue (ttm) | 4.44B +9.2% |
| Net Income | 29.45M -93.9% |
| EPS | 0.47 -93.7% |
| Shares Out | 62.74M |
| PE Ratio | 505.85 |
| Forward PE | 9.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,268,544 |
| Open | 234.21 |
| Previous Close | 229.55 |
| Day's Range | 232.05 - 238.55 |
| 52-Week Range | 105.00 - 238.55 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 248.76 (+4.76%) |
| Earnings Date | May 5, 2026 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price target is $248.76, which is an increase of 4.76% from the latest price.
News
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Jazz Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Zanidatamab shows strong efficacy and differentiation in HER2-positive cancers, with robust survival data and synergy with immunotherapies. Commercial teams are ready for launch, and expansion into new indications and partnerships is underway. The company also advances its sleep, epilepsy, and rare disease franchises.
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral with a price target of $307, up from $188. The firm cites improved confidence in Jazz’s base business…
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC ...
Jazz Pharmaceuticals price target raised to $245 from $226 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $245 from $226 and keeps an Overweight rating on the shares.
ALX Oncology evorpacept combination data presented at ESMO congress
ALX Oncology (ALXO) announced that data from exploratory analyses in the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceu...
Jazz Pharmaceuticals price target raised to $234 from $225 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $234 from $225 and keeps an Overweight rating on the shares following the Q1 report. Jazz…
Jazz Pharmaceuticals price target raised to $252 from $209 at Baird
Baird raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $252 from $209 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results…
Jazz Pharmaceuticals price target raised to $275 from $220 at TD Cowen
TD Cowen raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $275 from $220 and keeps a Buy rating on the shares. The firm said total Q1 revenue of…
Jazz Pharmaceuticals price target raised to $239 from $227 at Raymond James
Raymond James analyst Tiago Fauth raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $239 from $227 and keeps an Outperform rating on the shares. JAZZ is up 25%…
Jazz Pharmaceuticals Earnings Call Transcript: Q1 2026
Record Q1 revenues grew over 19% year-over-year, led by strong commercial execution in sleep, epilepsy, and oncology. Pipeline advances include FDA priority review for Ziihera in GEA and robust cash flow supports continued investment and M&A.
Jazz Pharmaceuticals Earnings release: Q1 2026
Jazz Pharmaceuticals released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Jazz Pharmaceuticals Quarterly report: Q1 2026
Jazz Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Jazz Pharmaceuticals Slides: Q1 2026
Jazz Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Jazz Pharmaceuticals reports Q1 adjusted EPS $6.34, consensus $4.66
GAAP EPS was $4.43. Reports Q1 revenue $1.07B, consensus $979.01M. “Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipe...
Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
16:10 EDT Jazz Pharmaceuticals (JAZZ) sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav® reven...
Jazz Pharmaceuticals’ sBLA for Ziihera combination in GEA accepted by FDA
Jazz Pharmaceuticals (JAZZ) announced that the FDA accepted for filing with Priority Review the supplemental Biologics License Application, or sBLA, for Ziihera – zanidatamab-hrii – containing combina...
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced tha...
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U...
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in...
Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $225 from $224 and keeps an Overweight rating on the shares. The firm adjusted ratings and…
Jazz Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Record revenue growth continues, with a sharpened focus on rare diseases and robust business development. Key pipeline assets like zanidatamab and Modeyso are advancing, while XYWAV and Epidiolex sustain strong performance. Multiple regulatory and clinical milestones are expected this year.
Jazz Pharmaceuticals resumed with an Outperform at Raymond James
Raymond James resumed coverage of Jazz Pharmaceuticals (JAZZ) with an Outperform rating and $227 price target The Jazz story has moved beyond the “it looks inexpensive/fairly valued, but where can…
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real-world evidence addressing rare neurological disorders, including rare and severe forms of epilep...